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ABSTRACT 
To investigate the safety profile and benefits of a short-term simultaneous treatment regimen combining two drugs—an 
intravitreal implant of dexamethasone with an intravitreal injection of bevacizumab—in patients with macular edema. 
This was a retrospective, non-randomized, open-label case series study.  Patients were treated between April 2014 and 
July 2015 and were diagnosed with recurrent macular edema secondary to diabetic retinopathy and retinal vein 
occlusion. They underwent simultaneous treatment with an intravitreal injection of bevacizumab (1.25 mg) and an 
intravitreal implant of dexamethasone (0.7 mg). Patients were evaluated at baseline and at each subsequent visit with a 
complete ophthalmological examination and spectral-domain optical coherence tomography (OCT) scans. They were 
examined 24 hours after the treatment, and then followed up after 30 days and 60 days. Twenty patients (representing 
20 eyes) were included in the study. At the time of injection (i.e., baseline), the best-corrected visual acuity (BCVA) was 
0.758 ± 0.42 logarithm of the minimum angle of resolution (logMAR). It improved significantly to 0.51 ± 0.33 logMAR at 1 
month and to 0.5 ± 0.34 logMAR at 2 months (P ≤ 0.03). The median baseline central macular thickness (CMT) was 542 
µm (interquartile range, 466 – 751 µm). The median CMT decreased significantly to 321 µm (interquartile range, 288–
381 µm) at 1 month and 310 µm (interquartile range, 286 – 354 µm) at 2 months (P ≤ 0.0002). The mean intraocular 
pressure (IOP) increased from 14.9 ± 2.29 mmHg (at baseline) to 16.5 ± 2.99 mmHg (P = 0.04) after 2 months. Two (10%) 
eyes showed cataract progression. There were no other ocular or systemic complications for the duration of this study. 
Simultaneous therapy combining a dexamethasone implant plus bevacizumab for macular edema may be an attractive 
treatment regimen with an acceptable safety profile. 
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INTRODUCION 
Macular edema (ME) occurs in many ocular pathologies 
(e.g., diabetic retinopathy and vein occlusion) and causes 
different degrees of visual impairment. Pathogenesis 
could be related to inflammatory cytokines (e.g., 
interleukin-6 and prostaglandin), dysregulation of 
endothelial tight junction proteins, and increased 
vascular endothelial growth factor (VEGF) expression (1-
5).
 
The expression of inflammatory factors breaks down 
the blood–retinal barrier, and thereby causes capillary 
leak, fluid accumulation, and increased macular thickness 
(3-5). Managing ME may involve laser therapy, 
intravitreal injections of anti-VEGF agents, or 
corticosteroid preparations. Several pharmacological 
treatment regimens have been introduced to treat ME 
such as intravitreal bevacizumab (Avastin; Genentech, 
Inc., South San Francisco, CA), ranibizumab (Lucentis; 
Genentech, Inc.), aflibercept (Eylea; Regeneron, Inc., 
Tarrytown, NY, USA), and a biodegradable intravitreal 
implant that slowly releases the corticosteroid 
dexamethasone (Ozurdex; Allergan, Inc, Irvine, CA) (3, 6). 
These pharmacological therapies have made it possible 
to improve vision rather than just stabilize it, and may 
significantly improve a patient’s quality of life (4).
 
Anti-
VEGF drugs decrease the concentration of free VEGF, but 
do not interfere with other proinflammatory molecules 
that mediate vascular permeability. Corticosteroids block 
the production of VEGF and other inflammatory 
mediators (5, 7). The combination of a corticosteroid 
with anti-VEGF drugs may substantially suppress vascular 
permeability and consequently decrease macular 
thickness, improve visual acuity, and increase the interval 
between injections, compared to the outcomes obtained 
with either of these medications alone—especially in 
eyes that present with severe edema (2, 3). The aim of 
this pilot study was to investigate the safety profile and 
benefits (i.e., improved visual acuity and decreased 
macular thickness) of short-term simultaneous treatment 
with an intravitreal injection of bevacizumab (1.25 mg) 
and intravitreal dexamethasone implant (0.7 mg) in 
patients with ME. 
 
 
MATERIALS AND METHODS 
This retrospective case series was a non-randomized, 
open-label, single-center investigation (Retina Clinic, São 
Paulo, Brazil). It was approved by the Institutional Review 
Board of Hospital Oftalmológico de Sorocaba/SP (São 
Paulo, Brazil) and adhered to the tenets of the 
Declaration of Helsinki. Study participants were patients 
older than 18 years who were treated between April 
2014 and July 2015, and diagnosed as having recurrent 
ME secondary to diabetic retinopathy and retinal vein 
occlusion. They underwent simultaneous treatment with 
an intravitreal injection of bevacizumab (Avastin [1.25 
mg]; Genentech, South San Francisco, CA) and an 
intravitreal dexamethasone implant (Ozurdex [0.7 mg]; 
Allergan, Inc, Irvine, CA). Patients with macular edema 
had a central macular thickness greater than 300 µm, 
based on spectral-domain optical coherence tomography 
(OCT). For this study, a variation greater than 6 mmHg in 
intraocular pressure (IOP) was considered abnormal. Key 
exclusion criteria were previous treatment with 
intravitreal anti-VEGF within 6 weeks and previous 
treatment with laser or intravitreal corticosteroids within 
3 months of study entry. 
 Patients were evaluated at baseline and at each 
subsequent visit with best-corrected Snellen visual acuity 
(BCVA) evaluation, slit-lamp examination, gonioscopy, 
indirect examination, intraocular pressure (IOP) 
measurement (Goldmann applanation tonometry), and 
spectral-domain OCT (Zeiss Cirrus, Dublin, CA). 
The procedure was performed in an operating room 
under sterile conditions. Two minutes before the 
injections, the patient received an initial drop of 
proparacaine (0.5%) onto the study eye, followed by 5% 
povidone-iodine solution. The eyelid margins, the eyelids 
and the periocular skin were then washed with 
povidone-iodine. The eye was draped in a sterile manner. 
A sterile lid speculum was inserted by the surgeon. A 
subconjunctival bleb of anesthesia was created by 
injecting 0.4 mL of lidocaine (1%) in the superior 
temporal quadrant. A caliper was used to mark the 
injection site 3.5 mm from the limbus in pseudophakic 
eyes and 4.0 mm in phakic eyes. A dexamethasone 
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implant (0.7 mg) was injected intravitreally, followed by 
bevacizumab (1.25 mg) in the superior temporal 
quadrant. Immediately after the injections, the patient’s 
visual acuity was tested to prevent visual loss due to 
increased IOP spikes. For 5 days after the procedure, 
patients used topical antibiotics (e.g., moxifloxacin). 
Twenty-four hours after the procedure, all patients were 
contacted via phone and questioned about symptoms of 
eye pain and worsening of visual acuity. They were then 
revaluated after 30 days and after 60 days. 
Statistical Analysis 
Descriptive analysis was used to present the 
demographic and clinical data. Data with normal 
distribution are presented as the mean ± the standard 
deviation (SD). Data with non-normal distribution are 
presented as the median (interquartile range). The 
independent samples t test was used to compare 
continuous normally distributed variables (i.e., IOP and 
visual acuity), whereas the Wilcoxon (signed-rank) test 
was used to compare non-normally distributed variables 
(i.e., macular thickness). Each parameter was compared 
at three time points: baseline (i.e., before treatment), 
and 30 days and 60 days after intravitreal injection of 
dexamethasone intravitreal implant and bevacizumab. 
MedCalc software (MedCalc Inc., Mariakerke, Belgium) 
was used for computerized statistical analysis. Statistical 
significance was set at P < 0.05. 
RESULTS 
Twenty patients (representing 20 eyes) with a mean age 
of 73.4 ± 8.9 years were included in the study. Table 1 
presents the patients’ baseline characteristics. Before 
study entry, 11 eyes were pseudophakic, five eyes were 
phakic, and four eyes had a cataract. At the time of 
injection (i.e., baseline), the BCVA was 0.758 ± 0.42 
logMAR and improved significantly to 0.51 ± 0.33 logMAR 
at 1 month and to 0.5 ± 0.34 logMAR at 2 months (P ≤ 
0.03). 
The median baseline central macular thickness (CMT) 
was 542 µm (interquartile range, 466–751 µm). The 
median CMT decreased significantly to 321 µm 
(interquartile range, 288–381 µm) at 1 month and to 310 
µm (interquartile range, 286 – 354 µm) at 2 months (P ≤ 
0.0002). Figure 1 presents the change in macular 
thickness after simultaneous treatment for 2 months. 
There was one case of ME recurrence after 2 months; the 
patient was treated with an anti-VEGF injection. 
 
 
Figure 1. The graph shows the change in macular thickness 
after simultaneous treatment during 2 months of follow up. IV, 
intravitreal. 
 
After 2 months, the mean IOP increased from 14.9 ± 2.29 
mmHg (at baseline) to 16.5 ± 2.99 mmHg (P = 0.04). Two 
(10%) eyes experienced increased IOP. However, in both 
patients, the IOP was controlled with two topical anti-
glaucoma medications. Deterioration of a pre-existing 
cataract occurred in 2 (10%) eyes, and 1 patient required 
cataract surgery. There were no treatment-related cases 
of iris and angle neovascularization, retinal detachment, 
vitreous hemorrhage, intraocular lens damage, ocular 
hypotony, endophthalmitis, or glaucoma surgery. 
DISCUSSION 
Many investigators have compared the use of an anti-
VEGF drug, followed by a low-release implant containing 
a corticosteroid drug to treat ME with intervals ranging 
from 2 weeks to 3 months between procedures (1-3). 
Few studies have used the concomitant therapy. Our 
data demonstrated the beneficial effects and the lack of 
serious adverse effects with this treatment modality. In 
this study, a simultaneous intravitreal injection of 
bevacizumab and a dexamethasone implant safely 
reduced ME and improved visual acuity during a 2-month 
follow up. 
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Table 1. Demographic and baseline characteristics, anatomic and functional results, and complications in patients with macular edema 
treated with a combined therapy 
Patient 
No. 
Sex Age Diagnosis Baseline Month 
1 
Month 
2 
Baseline Month 
1 
Month 
2 
Complications 
1 F 68 DME 810 517 464 0.7 0.5 0.4 None 
2 M 73 DME 460 381 335 1 1 1 Cataract 
progression 
3 M 82 CRVO 1416 296 290 1.3 0.6 0.6 None 
4 F 66 DME 427 280 277 0.5 1.3 1.4 Cataract 
progression 
5 M 50 DME 542 244 250 0.6 0.3 0.3 None 
6 F 85 BRVO 556 291 313 0.7 0.7 0.7 None 
7 M 66 CRVO 741 230 231 1.3 0.2 0.1 None 
8 F 73 DME 472 438 433 0.4 0.3 0.3 None 
9 F 68 CRVO 344 307 304 1.1 1.1 0.8 None 
10 M 70 DME 534 451 664 0.4 0.4 0.7 Increased IOP 
11 M 84 DME 382 321 309 0.3 0.3 0.3 None 
12 F 81 CRVO 1058 342 344 HM CF CF None 
13 F 70 DME 468 410 414 0.3 0.3 0.3 None 
14 M 78 CRVO 865 175 176 1.3 0.8 0.8 None 
15 M 74 BRVO 776 355 314 0.6 0.3 0.3 None 
16 F 80 BRVO 414 312 298 0.4 0.2 0.2 None 
17 F 63 BRVO 743 217 214 1.7 0.5 0.4 None 
18 M 71 DME 528 308 301 0.6 0.3 0.2 Increased IOP 
19 F 87 BRVO 522 384 385 1 0.6 0.6 None 
20 F 80 BRVO 572 321 310 0.2 0.1 0.1 None 
BCVA: best-corrected visual acuity; BRVO: branch retinal vein occlusion; CF: counting fingers; CMT: central macular thickness; CRVO: 
central retinal vein occlusion; DME: diabetic macular edema; HM: hand movement; IOP: intraocular pressure; logMAR: logarithm of the 
minimum angle of resolution. 
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This study is among the first studies to investigate this 
treatment regimen. During the first month, the central 
macular thickness decreased significantly (P = 0.0001), 
and this reduction remained significant at the end of the 
second month (P = 0.0002; Figure 2). Visual acuity 
improved significantly after 30 days and 60 days of follow 
up (P ≤ 0.03). 
 
Figure 2. Optical coherence tomography retinal images of 
representative study eyes with DME, CRVO, and BRVO at 
baseline and after treatment with dexamethasone implant and 
bevacizumab. Optical coherence tomography indicates central 
macular edema. BRVO, branch retinal vein occlusion; CMT, 
central macular thickness; CRVO, central retinal vein occlusion; 
DME, diabetic macular edema; OCT, optical coherence 
tomography. 
 
Our data compares favorably with the data of previous 
studies. For example, Michael et al. (2) demonstrated 
progressive mean visual improvement within 2 weeks in 
individuals with vein occlusion after they received 
combined therapy. Raj et al. (3) showed that 1 month 
after combined therapy, edema in patients with diabetic 
ME dramatically improved, and this improvement was 
sustained for at least 3 months. The increase in IOP after 
2 months was significant (P = 0.04); however, we believe 
that the mean elevation of IOP (1.6 mmHg) could be 
attributed to variations in measurements without clinical 
impact. The increase in IOP in our patients may not have 
increased, as described in other studies (8-13), because 
of the limited follow up period of our investigation. Many 
patients who have barriers to a monthly follow-up 
regimen or who have disease recurrence may become a 
significant burden. For these patients, simultaneous 
treatment may result in a fewer number of procedures 
and may be more beneficial and comfortable (14).
 
In the 
present series, the concomitant therapy was well 
tolerated. 
A limitation of our study is that it was retrospective, 
nonrandomized, and uncontrolled. The follow up lasted 
only 2 months; therefore, it was impossible to estimate 
the long-term efficacy and safety of the dexamethasone 
implant and the need for reinjection. In addition, 
because of the lack of a control group, we cannot rule 
out the possibility that the reduction in the macular 
thickness may be associated with better systemic control, 
especially in patients with diabetic ME. It is possible that 
the low rate of the progression of cataracts could be 
related to the short follow-up period and reduced 
number of injections. In summary, simultaneous therapy 
of dexamethasone implant and bevacizumab for macular 
edema may be an attractive treatment regimen with an 
acceptable safety profile. Further trials are indicated to 
better define the long-term efficacy and adverse effects 
of this regimen. 
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